NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on ...

Helius Medical (HSDT) Technologies announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis. PoNSTEP Results: There were ...

(RTTNews) - Helius Medical Technologies (HSDT), a neurotech company focused on innovative treatments for neurological deficits, on Tuesday announced strong progress in its stroke registrational ...

NEWTOWN, Pa. - Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company with a market capitalization of $2.8 million, has surpassed its initial enrollment target for its stroke ...

--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis ...

Helius Medical Technologies, Inc. announced agreements with warrant holders to exercise nearly 4.97 million shares of common stock at a reduced price of $0.751 per share, generating approximately ...

Helius Medical Technologies, Inc. (Nasdaq: HSDT) has made headlines after a jaw-dropping surge in its stock price, which shot up by an astounding +5712.38% to $1.18 in Tuesday’s premarket trading ...

On Tuesday, Helius Medical Technologies Inc (HSDT) stock saw a modest uptick, ending the day at $1.03 which represents a slight increase of $0.28 or 37.33% from the prior close of $0.75. The stock ...

After hours: January 24 at 5:25:37 PM EST Loading Chart for FR ...